Saratoga Investment Corp. NT 23 (SAB) Research

Saratoga Investment Corp. offers capital solutions to mid-sized businesses, encompassing both loan facilities and direct equity investments.

Market snapshot

Symbol
SAB
Price
$25.62
Day change
-0.12%
Market cap
$150.8M
52-week range
25.6713-211000.0
Sector
Financial Services
Industry
Asset Management
Analyst price target
$20.00

Recent news

  • OKYO Pharma advances clinical strategy with SAB meeting and ASCRS presentation

    OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on treatments for neuropathic corneal pain (NCP) and inflammatory eye diseases, has announced plans to convene a Scientific Advisory Board (SAB) meeting during the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C. The SAB meeting will bring together ophthalmology specialists and experts in corneal and ocular surface diseases to review clinical data for the company's lead investigational candidate, urcosimod.

Peer companies

  • BCP Investment Corporation (BCIC)
  • Blockchain Coinvestors Acquisition Corp. I (BCSA)
  • Crescent Capital BDC, Inc. (CCAP)
  • BNY Mellon Municipal Income, Inc. (DMF)
  • FNCB Bancorp, Inc. (FNCB)
  • Learn CW Investment Corporation (LCW)
  • Oxford Square Capital Corp. (OXSQ)
  • Salisbury Bancorp, Inc. (SAL)

Open Saratoga Investment Corp. NT 23 (SAB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.